Login to Download
PDF version

     Travis E. Baugh, President and Chief Operating Officer of Healthpoint, Ltd. offers an up close and personal look inside the company’s vital role in the wound care industry and his day-to-day roles and responsibilities in overseeing the business as its corporate commander-in-chief.

CH: Please describe your work experiences that prepared you for your current position as President and Chief Operating Officer of Healthpoint:

     TB: I have been a member of Healthpoint’s parent company Board of Directors (DFB Pharmaceuticals) since 2004. Having that background helped me immensely in my transition to a full time role in 2008. Prior to joining Healthpoint, I was CEO of MicroMed Cardiovascular, Inc., a medical device company that developed the DeBakey VAD®, a miniaturized ventricular assist device, in collaboration with NASA and Dr. Michael DeBakey’s team at the Baylor College of Medicine. In that role, I dealt with all aspects of the healthcare system, including navigating the complex regulatory environments from our US Food and Drug Administration and various international regulatory agencies, confronting reimbursement issues from both private and public payors and the challenges of manufacturing, selling and distributing a technologically challenging product line.

CH: What are some specific things our readers should know about Healthpoint?

     TB: Healthpoint, Ltd. is a privately held specialty pharmaceutical company headquartered in Fort Worth, Texas that is dedicated to innovative technologies that serve the wound care, burn, and skin asepsis markets. We are a fully integrated specialty pharmaceutical company with dedicated R&D, regulatory, and marketing functions; as well as an institutional-based US sales force of more than 140 sales representatives. Healthpoint is also committed to advancing the care and treatment of wounds through the development of advanced cellular technologies, as well as support of industry leading continuing education from THE WOUND INSTITUTE®.

CH: How were you first introduced to wounds and wound care and why do you enjoy working in this evolving arena?

     TB: I first became exposed to advanced wound care while at MicroMed where I became aware of a unique thrombin peptide technology that was in clinical trials for the treatment of venous leg ulcers. We licensed the technology so it could be applied to the heart muscle with the objective of repairing or regenerating infarcted myocardial cells. Most of what I have learned about wound care has occurred through my professional positions and relationship with DFB and Healthpoint. What I find most satisfying about this area of medicine is that wound care is a very compelling human need. We make products that help people heal.

CH: How does Healthpoint value tissue management and infection prevention?

     TB: Healthpoint’s principal business is in the tissue management/wound care sector, with most of our products and resources focused in that area. However, we also have a small group of professionals dedicated to the operating room environment. Infection prevention in that arena is of critical importance, particularly now that hospitals are not able to charge Medicare for hospital-acquired infections. We have developed a line of anti-infection products, including TRISEPTIN® Antiseptic Surgical scrub and SURGICEPT® Waterless Surgical scrub with a patented formulation that provides persistent antibacterial protection. Both have skin emollients that help moisturize the hands of professionals who use these types of products several times each day.